Characteristics of Study Cohort
| Patient characteristic (n = 73) | Median or absolute number* |
| Age (y) | 52 (IQR, 24) |
| Sex | |
| Female | 37 (51%) |
| Male | 36 (49%) |
| Site | |
| Head and neck | 3 (4%) |
| Chest and trunk | 7 (10%) |
| Abdomen and retroperitoneum | 36 (49%) |
| Extremities | 27 (37%) |
| Histology | |
| Angiosarcoma | 6 (8%) |
| Leiomyosarcoma | 13 (18%) |
| Liposarcoma | 13 (18%) |
| MPNST | 6 (8%) |
| Synovial sarcoma | 4 (5%) |
| Pleomorphic undifferentiated sarcoma | 15 (21%) |
| Other | 16 (22%) |
| FNCLCC grade | |
| 1 | 1 (1%) |
| 2 | 22 (30%) |
| 3 | 50 (69%) |
| Stage | |
| Recurrent tumor | 18 (25%) |
| Primary tumor | 55 (75%) |
| Radiotherapy | |
| Yes | 30 (41%) |
| No | 43 (59%) |
| Surgery | |
| After chemotherapy | 34 (47%) |
| Before chemotherapy | 27 (37%) |
| No surgery | 12 (16%) |
| Chemotherapy | |
| AI | 66 (90%) |
| EDIC | 3 (4%) |
| Mini-ICE | 4 (6%) |
| Progression (events) | |
| Local | 27 (37%) |
| Distant | 24 (33%) |
| Local plus distant | 37 (51%) |
| Deaths | 19 (26%) |
| Time to event overall (mo) | 15.3 (IQR, 17.7) |
| Overall survival (mo) | 22.2 (IQR, 17.3) |
| Time of follow-up (mo) | 22.2 (IQR, 17.3) |
| No. of therapy courses between PET scans | 3 (IQR, 2) |
| No. of therapy courses from second PET to surgery | 1 (IQR, 2) |
* Data are median, with IQR in parentheses, or absolute number (with % in parentheses).
MPNST = malignant peripheral nerve sheath tumor; FNCLCC = French Fédération Nationale des Centers de Lutte Contre le Cancer.